Simplex Trading’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.7K Buy
+278
New +$20.3K ﹤0.01% 6917
2025
Q3
Sell
-145
Closed -$2.36K 10047
2025
Q2
$2K Buy
+145
New +$2.15K ﹤0.01% 8211
2025
Q1
Sell
-55
Closed -$1.14K 9651
2024
Q4
$1K Buy
+55
New +$1.61K ﹤0.01% 8323
2024
Q3
Sell
-64
Closed -$1K 9554
2024
Q2
$1K Buy
+64
New +$2.16K ﹤0.01% 8569
2023
Q3
Sell
-112
Closed -$1K 9787
2023
Q2
$1K Buy
112
+110
+5,500% +$522 ﹤0.01% 8726
2023
Q1
$0 Hold
2
﹤0.01% 10110
2022
Q4
$0 Sell
2
-523
-100% -$9.4K ﹤0.01% 10401
2022
Q3
$6K Buy
525
+524
+52,400% +$6.47K ﹤0.01% 8687
2022
Q2
$0 Buy
+1
New +$35 ﹤0.01% 11068
2021
Q1
Sell
-5
Closed -$959 9993
2020
Q4
$0 Buy
5
+2
+67% +$415 ﹤0.01% 9069
2020
Q3
$0 Sell
3
-27
-90% -$5K ﹤0.01% 8495
2020
Q2
$6K Buy
30
+29
+2,900% +$5.52K ﹤0.01% 6908
2020
Q1
$0 Sell
1
-28
-97% -$4.76K ﹤0.01% 8248
2019
Q4
$5K Sell
29
-23
-44% -$4.51K ﹤0.01% 6718
2019
Q3
$10K Sell
52
-33
-39% -$6.43K ﹤0.01% 6262
2019
Q2
$14K Buy
+85
New +$14.7K ﹤0.01% 5907

Other funds holding SYRE

Simplex Trading's SYRE Position: Q2 2026 in Review

Simplex Trading opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 278 shares worth $24.7K. The stake represents ﹤0.01% of the portfolio and ranks #6917 among its holdings. This is a return to the name: Simplex Trading previously reported a position in SYRE as recently as Q2 2025.

Simplex Trading first reported a position in SYRE in Q2 2019 and has held it in 16 quarters since. 267 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Simplex Trading held 278 shares of Spyre Therapeutics worth $24.7K as of Q2 2026.
  • Spyre Therapeutics was a new Simplex Trading position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #6917 holding.
  • Simplex Trading first reported a position in Spyre Therapeutics in Q2 2019 and has held it in 16 quarters since.
  • 267 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.